Last reviewed · How we verify
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward. Adutt patients from risk group (receiving immunosuppressive drugs and treated with antibiotics) were enrolled into study. Patients who meet the above criteria for inclusion in the study will be assigned to one of two groups. Patients in group I (study) will receive a probiotic containing the Lactobacillus plantarum 299v strain of bacteria as part of the prophylaxis of Clostridioides difficile infection. The daily dose is 1 capsule containing approximately 10x109 colony-forming units of live bacteria taken orally with a meal. Patients in group II (control) will receive a placebo. The duration of probiotic or placebo use will be 3 months. Assignment to groups I and II will be random. The number of patients in each group will be 150. Participants will be divided into two groups. First group will receive one capsule of Lactobacillus plantarum 299v (LP299v) orally per a day. Second group will receive placebo. The observation period will last 3 months. The evaluation will consist of an interview, physical examination and laboratory tests.
Details
| Lead sponsor | Medical University of Silesia |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 300 |
| Start date | Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Oct 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Clostridioides Difficile Infection
Interventions
- Prevention of C. difficile infections using LP299v strain Placebo
- Prevention of C. difficile infections using LP299v strain LP299v
Countries
Poland